课题基金 / 基金详情

EFFICACY, SAFETY AND TOLERANCE OF ORAL ZIDOVUDINE IN HIV EXPOSED INFANT

EFFICACY, SAFETY AND TOLERANCE OF ORAL ZIDOVUDINE IN HIV EXPOSED INFANT
口服齐多夫定对 HIV 暴露婴儿的疗效、安全性和耐受性
批准号：
2787604
负责人：
金额：
$1.94万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/2787604
关键词：
AIDS therapy HIV infections chemoprevention clinical research drug screening /evaluation female human pregnant subject human subject human therapy evaluation infant human (0-1 year) microorganism disease chemotherapy newborn human (0-6 weeks) perinatal pregnancy vertical transmission zidovudine

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This multicenter, Phase 3 randomized placebo controlled trial is designed to determine whether the vertical HIV transmission rate can be reduced by continuous oral ZDV administration to HIV infected pregnant women between 14-34 weeks gestation, also giving an intrapartum intravenous dose and oral ZDV administration to their newborn infants from birth to six weeks of age. This study also designed to evaluate the safety of ZDV for both the pregnant woman and for the newborn infants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金